Alkermes Controlled Therapeutics, Inc. Ii

Alkermes, Inc.

Alkermes Pharma Ireland Limited

Janssen Pharmaceutica

Other

Amylin Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

Alkermes Controlled Therapeutics, Inc.

Alkernnes Pharma Ireland Limited

Thomas J. Atkins

Michael E. Rickey

Jean Louis Mesens

Danny H. Lewis

J. Michael Ramstack

Michael E Rickey

Rajesh Kumar

J Michael Ramstack

Steven G Wright

Joyce M Hotz

Henry R Costantino

Thomas J Atkins

Thean Yeoh

Troy Christensen

Danny H Lewis

Shawn L Lyons

Mark S Fineman

Christine Smith

John Ong

David M Lokensgard

Thean Y Yeoh

Thean Y Yeah

Troy Christenson

David Lokensgard

Henry Constantino

Michael J Ramstack

David Lokensgord

This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.

Polymer-based sustained release device

Poly(lactide-co-glycolide) based sustained release microcapsules comprising a polypeptide and a sugar

Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.

Residual solvent extraction method and microparticles produced thereby

Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.

Growing community of inventors

Loveland, OH, United States of America

Michael E Rickey